

## PRODUCT INFORMATION

<b>Tag</b>	<b>Warning:</b> Undefined variable \$hasAttributeValueDescription in C:\wwwroot\mirror.dimabio.com\wp-content\plugins\woocommerce-print-products\publicclass-woocommerce-print-products-public.php on line 2806 C-Flag Tag
<b>Target</b>	CGRPR
<b>Synonyms</b>	CALCRL; CRLR; LMPHM8
<b>Description</b>	Human CGRPR-RAMP1 full length protein membrane nanoparticles (MNP)
<b>Delivery</b>	In Stock
<b>Uniprot ID</b>	Q16602
<b>Expression Host</b>	HEK293
<b>Protein Families</b>	Druggable Genome, GPCR, Transmembrane
<b>Protein Pathways</b>	Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction
<b>Molecular Weight</b>	The human full length CGRPR protein has a MW of 53.0 kDa
<b>Formulation &amp; Reconstitution</b>	Lyophilized from sterile PBS, pH 7.4. Normally 5% - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
<b>Yefei_Storage</b>	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
<b>Background</b>	The CGRP receptor (CGRPR) is a member of family B G protein coupled receptors (GPCRs), is expressed throughout the trigeminal system, including neurons and endothelial cells. They usually function with accessory proteins such as receptor activity modifying proteins (RAMPs) and Na/H exchange regulatory factors (NHERFs). CGRPR is a heterodimer complex of the calcitonin receptor-like receptor (CRLR) and receptor activity-modifying protein 1 (RAMP1). Therapeutics for migraine treatment are mostly targeting CRLR-RAMP1 protein-protein interaction surfaces, thereby blocking CGRP activity.
<b>Usage</b>	Research use only
<b>Conjugate</b>	Unconjugated

### ELISA assay to evaluate CGRPR-RAMP1-MNP 0.5µg Human CGRPR-RAMP1-MNP per well




Figure1. Elisa plates were pre-coated with 0.5µg/per well purified human CGRPR-RAMP1 full length membrane nanoparticles. Serial diluted anti-CGRPR monoclonal antibody (BME100166) solutions were added, washed, and incubated with secondary antibody before Elisa reading. From above data, the EC50 for anti-CGRPR monoclonal antibody binding with CGRPR-RAMP1 full length membrane nanoparticles is 122.8ng/ml.

